Added to YB: 2026-07-03
Pitch date: 2026-06-30
NEUP [neutral]
Neuphoria Therapeutics Inc.
-23.53%
current return
Author Info
No bio for this author
Company Info
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Market Cap
$23.6M
Pitch Price
$4.42
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.30
P/E
-0.88
EV/Sales
-317.44
Sector
Biotechnology
Category
special_situation
KEDM Lite Vol. 20 - Neuphoria Therapeutics Inc.
NEUP (update): Failed AFFIRM-1 Phase 3 (BNC210, social anxiety) triggered strategic review; shares dropped, but Lynx1 aggressively bought to 37% stake. June 2026: Scancell in advanced talks for all-share reverse-merger, seeking equity/debt to fund Phase 3 melanoma asset iSCIB1+.
Read full article (1 min)